{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:36:14Z","timestamp":1769506574260,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jctejournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical & Translational Endocrinology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jcte.2024.100332","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T06:24:39Z","timestamp":1709101479000},"page":"100332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The Changing Landscape of Treatment for Cystic Fibrosis Related Diabetes"],"prefix":"10.1016","volume":"35","author":[{"given":"Mehdia","family":"Amini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Liebich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaishaliben","family":"Ahir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stewart","family":"Albert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9342-9807","authenticated-orcid":false,"given":"Sandeep","family":"Dhindsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jcte.2024.100332_b0005","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1210\/clinem\/dgac020","article-title":"New concepts in the pathogenesis of cystic fibrosis-related diabetes","volume":"107","author":"Moheet","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.jcte.2024.100332_b0010","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2337\/db22-0949","article-title":"Cystic fibrosis-related diabetes workshop: research priorities spanning disease pathophysiology, diagnosis, and outcomes","volume":"72","author":"Putman","year":"2023","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.jcte.2024.100332_b0015","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98240","article-title":"Cystic fibrosis-related diabetes is caused by islet loss and inflammation","volume":"3","author":"Hart","year":"2018","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.jcte.2024.100332_b0020","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jcf.2011.11.001","article-title":"Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus","volume":"11","author":"Hillman","year":"2012","journal-title":"J Cyst Fibros"},{"issue":"12","key":"10.1016\/j.jcte.2024.100332_b0025","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: A position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcte.2024.100332_b0030","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jcf.2019.08.016","article-title":"Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis","volume":"18","author":"Granados","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcte.2024.100332_b0035","article-title":"Cystic fibrosis related diabetes (CFRD) prognosis","volume":"26","author":"Sandouk","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"issue":"3","key":"10.1016\/j.jcte.2024.100332_b0040","doi-asserted-by":"crossref","first-page":"e220740","DOI":"10.1001\/jamanetworkopen.2022.0740","article-title":"Association of body mass index with clinical outcomes in patients with cystic fibrosis: a systematic review and meta-analysis","volume":"5","author":"Nagy","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.jcte.2024.100332_b0045","first-page":"Cd010966","article-title":"Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)","volume":"12","author":"Southern","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"19","key":"10.1016\/j.jcte.2024.100332_b0050","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcte.2024.100332_b0055","article-title":"Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes","volume":"33","author":"Lurquin","year":"2023","journal-title":"J Clin Transl Endocrinol"},{"issue":"9","key":"10.1016\/j.jcte.2024.100332_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/nu13092907","article-title":"The impact of highly effective CFTR modulators on growth and nutrition status","volume":"13","author":"Bass","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.jcte.2024.100332_b0065","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jpeds.2018.05.018","article-title":"Energy balance and mechanisms of weight gain with ivacaftor treatment of cystic fibrosis gating mutations","volume":"201","author":"Stallings","year":"2018","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.jcte.2024.100332_b0070","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcte.2024.100332_b0075","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jcf.2020.03.002","article-title":"Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients","volume":"19","author":"Misgault","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcte.2024.100332_b0080","article-title":"Glycemia and \u03b2-cell function before and after elexacaftor\/tezacaftor\/ivacaftor in youth and adults with cystic fibrosis","volume":"30","author":"Chan","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"issue":"5","key":"10.1016\/j.jcte.2024.100332_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101466","article-title":"Effects of elexacaftor \/ tezacaftor \/ ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes","volume":"49","author":"Grancini","year":"2023","journal-title":"Diabetes Metab"},{"issue":"2","key":"10.1016\/j.jcte.2024.100332_b0090","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcte.2024.100332_b0095","article-title":"CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor-tezacaftor-ivacaftor therapy","volume":"30","author":"Crow","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"issue":"2","key":"10.1016\/j.jcte.2024.100332_b0100","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"10","key":"10.1016\/j.jcte.2024.100332_b0105","first-page":"CD004730","article-title":"Drug treatments for managing cystic fibrosis-related diabetes","volume":"10","author":"Onady","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.jcte.2024.100332_b0110","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S2213-8587(17)30400-X","article-title":"Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial","volume":"6","author":"Ballmann","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.jcte.2024.100332_b0115","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1210\/clinem\/dgab365","article-title":"Effect of sitagliptin on islet function in pancreatic insufficient cystic fibrosis with abnormal glucose tolerance","volume":"106","author":"Kelly","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.jcte.2024.100332_b0120","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa167","article-title":"Semaglutide in cystic fibrosis-related diabetes","volume":"105","author":"Gnanapragasam","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jcte.2024.100332_b0125","article-title":"Obesity in cystic fibrosis","volume":"26","author":"Kutney","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"issue":"9","key":"10.1016\/j.jcte.2024.100332_b0130","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.clnu.2019.12.029","article-title":"Overweight, obesity and significant weight gain in adult patients with cystic fibrosis association with lung function and cardiometabolic risk factors","volume":"39","author":"Bonhoure","year":"2020","journal-title":"Clin Nutr"},{"issue":"4","key":"10.1016\/j.jcte.2024.100332_b0135","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jcf.2019.01.009","article-title":"The main mechanism associated with progression of glucose intolerance in older patients with cystic fibrosis is insulin resistance and not reduced insulin secretion capacity","volume":"18","author":"Colomba","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcte.2024.100332_b0140","article-title":"Link between insulin resistance and obesity-from diagnosis to treatment","volume":"12","author":"Go\u0142acki","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"Suppl 1","key":"10.1016\/j.jcte.2024.100332_b0145","first-page":"S158","article-title":"Standards of Care in Diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"}],"container-title":["Journal of Clinical & Translational Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214623724000036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214623724000036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:57:39Z","timestamp":1762005459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214623724000036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":29,"alternative-id":["S2214623724000036"],"URL":"https:\/\/doi.org\/10.1016\/j.jcte.2024.100332","relation":{},"ISSN":["2214-6237"],"issn-type":[{"value":"2214-6237","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Changing Landscape of Treatment for Cystic Fibrosis Related Diabetes","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical & Translational Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcte.2024.100332","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100332"}}